Reply to T.J.A. Dekker

Affiliation

• ¹ Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Haeseong Park, MD, MPH, Washington University School of Medicine, St Louis, MO; Rashmi K. Murthy, MD, MBE, University of Texas MD Anderson Cancer Center, Houston, TX; Hiroji Iwata, PhD, MD, Aichi Cancer Center Hospital, Nagoya, Japan; Kenji Tamura, MD, PhD, National Cancer Center Hospital, Tokyo, Japan; Junji Tsurutani, MD, PhD, Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan and Kindai University Faculty of Medicine, Osaka, Japan; Alvaro Moreno-Aspitia, MD, Mayo Clinic, Jacksonville, FL; Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan; Yasuaki Sagara, MD, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan; Charles Redfern, MD, Sharp HealthCare, San Diego, CA; Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute, Boston, MA; Caleb Lee, MD, PhD, Daiichi Sankyo, Basking Ridge, NJ; Yoshihiko Fujisaki, MS and Masahiro Sugihara, PhD, Daiichi Sankyo, Tokyo, Japan; Lin Zhang, MD, PhD and Javad Shahidi, MD, Daiichi Sankyo, Basking Ridge, NJ; and Shunji Takahashi MD, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.